Breath Analysis as a Possible Way to Detect Cancer Early
Studies chemicals in the breath of adults with several types of cancer.
Plain-language title generated from the registry record
Registry title: Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry
Key facts
- Where
- Oklahoma City, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with any type of cancer, newly diagnosed or established, who are not on active cancer treatment. Breath samples will be analysed.
- Age
- 18 years or older
- Sex
- Men and women can join
- Disease stage
- Cancer of any type. Either newly diagnosed and untreated, or an established diagnosis with no active anti-cancer treatment for more than one month.
- Earlier treatment
- New cancer: untreated. Established cancer: no active anti-cancer treatment for more than one month.
Main reasons for not taking part
- Under 18 years old
- Pregnant women
- Active respiratory infection symptoms
- Recent use of antibiotics
- On active cancer treatment, or treated within one month
Read by machine on 9 November 2026.
Where in United States
- OU Health Stephenson Cancer CenterOklahoma City, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Oklahoma
- Trial code
- NCT07732686
- Record updated
- 29 July 2026
- Original description
The purpose of this clinical trial is to evaluate whether volatile organic compound (VOC) signatures detected in the breath of patients with cancer can serve as a potential screening tool for the early detection of cancer.Read full original descriptionShow less
Breath Volatile Organic Compounds (VOC) Analysis Using Proton Transfer Reaction Mass Spectrometry (PTR-MS)
The purpose of this clinical trial is to evaluate whether volatile organic compound (VOC) signatures detected in the breath of patients with cancer can serve as a potential screening tool for the early detection of cancer.
Inclusion: Age ≥ 18 at the time of consent. Male and female patients to be tested; Capable of understanding written and/or spoken English language; Able to provide informed consent; Cancer of any type; Newly diagnosed cancer and untreated or established diagnosis of cancer. For established cancer patients, no active anti-cancer treatment for more than one month (reasons for no treatment are such as relapse, progression of cancer, refractory, or intolerance to treatment etc.).
Exclusion: Cancer patients who are on active treatment for cancer or have received cancer treatment within one month; Active respiratory infection symptoms; Under the age of 18; Anticipated inability to complete breath sampling procedure; Unable to provide informed consent; Pregnant women; Recent use of antibiotics; Difficulty in performing coached exhalation; Individuals who are unable to follow the instructions.